News & Events

Can mRNA Facilities Really be Flexible? Four Key Questions to Accommodate Growth and Expansion

Tuesday 13 July 2021

The pharmaceutical industry is increasingly embracing modular facility design when creating spaces for manufacturing treatments, vaccines, and other pharma products. Such agile or flexible facilities often promise the capability of modifying design as easily as swapping out building blocks, creating an easier and more cost-conscious way to expand capabilities as the business grows.

Read DPS Group's Jeffrey Heil’s article “Can mRNA Facilities Really Be Flexible?” featured in Contract Pharma, where Jeff answers four key questions to accommodate growth and expansion for your facility.

Read the article now.

Back to top